WASHINGTON — President Trump’s nominee to head the Department of Health, Robert F. Kennedy Jr., has invested in gene-editing technology and owes substantial advances on several books, according to financial disclosures released ahead of his hearings in confirmation.
The disclosures provide the clearest view yet of RFK Jr’s investments, employment and potential conflicts of interest. They show he plans to divest his shares, including his stakes in biotechnology companies CRISPR Therapeutics AG and Dragonfly Therapeutics. He is also leaving positions at his law firm and the anti-vaccine nonprofit Children’s Health Defense.
Trump tapped RFK Jr. to lead the Department of Health and Human Services after Kennedy ended his presidential campaign and supported Trump. Confirmation hearings have not yet been scheduled.
This article is reserved for STAT+ subscribers
Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.
Already have an account? Log in
See all packages
